青春期抑制与性激素对丹麦跨性别青少年体重、BMI及血脂的影响
这项观察性研究纵向随访了164名跨性别男孩和55名跨性别女孩,他们在18岁前开始激素治疗。基线时超重和肥胖常见,BMI SDS与血脂异常相关;GnRHa单药期间体重SDS有下降趋势但BMI与血脂无一致变化;启动性激素后,跨性别男孩体重SDS、BMI SDS与HDL下降、甘油三酯升高,跨性别女孩HDL升高。结论为激素治疗前超重、肥胖和血脂异常常见,性激素治疗期间BMI未恶化但跨性别男孩血脂异常轻度加重。
要点
- 激素治疗前跨性别青少年超重、肥胖和血脂异常常见,应基线评估血脂。
- GnRHa单药期间BMI SDS与血脂无一致变化,体重SDS有下降趋势。
- 跨性别男孩启动性激素后HDL下降、甘油三酯升高,血脂异常轻度加重。
核心结论
- 在跨性别青少年中,激素治疗前超重、肥胖和血脂异常常见。
- 性激素治疗期间BMI未恶化,但跨性别男孩血脂异常轻度加重,跨性别女孩未见加重。
研究设计与样本
- 观察性研究,纳入164名跨性别男孩和55名跨性别女孩,均为18岁前开始激素治疗。
- GnRHa在性激素治疗之前或同时启动,纵向随访人体测量与血脂。
- 在激素治疗开始及常规随访时分析人体测量学与血脂谱。
主要发现
- 激素治疗前,跨性别男孩超重(BMI 1-2 SDS)占26.8%、肥胖(BMI ≥2 SDS)占22.0%,跨性别女孩分别为5.7%和5.7%。
- BMI SDS与总胆固醇、LDL和甘油三酯正相关,与HDL负相关。
- 跨性别男孩和女孩血脂高于正常参考区间者比例分别为:总胆固醇12.5%和6.1%、LDL 21.8%和12.5%、甘油三酯3.4%和6.3%;HDL低于正常参考区间者分别为9.0%和18.4%。
- GnRHa单药治疗期间体重SDS有下降趋势,但BMI SDS和血脂谱无一致变化。
- 启动性激素后,跨性别男孩体重SDS、BMI SDS和HDL下降且甘油三酯升高,跨性别女孩HDL升高。
临床怎么用
- 跨性别青少年启动激素治疗前应评估体重、BMI和血脂,识别已有超重、肥胖和血脂异常者。
- GnRHa单药期间可监测体重变化,但BMI与血脂无一致变化,不必据此预期血脂改善。
- 跨性别男孩启动性激素后应关注HDL下降和甘油三酯升高,跨性别女孩应关注HDL变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Cardiovascular health of the transgender population receiving hormone therapy (HT) has been a concern. OBJECTIVE: To investigate weight, body mass index (BMI), and lipid profiles in a national cohort of transgender adolescents starting HT before 18 years of age. METHODS: In this observational study, 164 trans boys and 55 trans girls were followed longitudinally during HT. Gonadotropin-releasing hormone analog (GnRHa) was initiated either before or alongside sex steroid therapy. Anthropometry and lipid profiles were analyzed at the start of HT and at routine visits. RESULTS: Before HT, overweight (BMI 1-2 standard deviation score [SDS]) and obesity (BMI ≥ 2 SDS) were found in 26.8% and 22.0% of trans boys, and in 5.7% and 5.7% of trans girls, respectively. BMI SDS correlated positively with total cholesterol, low-density lipoprotein (LDL), and triglycerides, and negatively with high-density lipoprotein (HDL). In trans boys and girls, high percentages had lipids above normal reference intervals; total cholesterol (12.5% and 6.1%), LDL (21.8% and 12.5%), and triglycerides (3.4% and 6.3%), and HDL below normal reference intervals (9.0% and 18.4%), respectively. During GnRHa monotherapy, there was a trend toward declining weight SDS, but BMI SDS and lipid profiles did not change consistently. After initiation of sex steroids, weight SDS, BMI SDS, and HDL decreased along with increased triglycerides in trans boys, and HDL increased in trans girls. CONCLUSION: Overweight, obesity, and dyslipidemia were common in transgender adolescents before HT initiation. BMI did not deteriorate, but dyslipidemia worsened slightly during sex steroid therapy in trans boys but not in trans girls.
引用
- Kvernebo Sunnergren K, Norup PB, Haahr ME, et al. Effects of Puberty Suppression and Sex Steroids on Weight, BMI, and Lipid Profiles in Danish Transgender Adolescents. J Clin Endocrinol Metab. 2026. PMID: 41054822. doi:10.1210/clinem/dgaf549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。